Intero Biosystems Offers Lab‑Grown Human Intestines to Replace Animal Testing

Intero Biosystems is marketing lab‑grown human intestinal organoids to pharmaceutical companies as a substitute for traditional animal testing. The company says its mini‑intestines can mimic human drug absorption and toxicity more accurately than animal models.

Regulators in the United States and Europe have been urging the industry to adopt non‑animal testing methods, and Intero is scaling its production to meet anticipated demand. The startup plans to broaden its organoid platform beyond the gut, aiming to create a suite of human‑derived tissues for drug screening.

By providing a reproducible, human‑based testing tool, Intero hopes to shorten development timelines and reduce the ethical concerns associated with animal experiments, while offering drugmakers a potentially more predictive safety assessment.

Why It Matters

The shift toward human‑based testing aligns with tightening US and EU regulations that seek to reduce animal use and improve drug safety predictions.